{
  "id" : "seer_primary_tumor_59317",
  "algorithm" : "eod_public",
  "version" : "2.1",
  "name" : "EOD Primary Tumor",
  "title" : "EOD Primary Tumor",
  "notes" : "**Note:** In case of multifocal papillary noninvasive tumors (code 000) and nonpapillary in situ tumors (code 050), code 050.",
  "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Hansel, D.E., Reuter, V.E., McKiernan, J.M., et al. **Urethra**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017",
  "last_modified" : "2021-04-08T19:00:41.807Z",
  "definition" : [ {
    "key" : "eod_primary_tumor",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  }, {
    "key" : "eod_2018_t",
    "name" : "EOD 2018 T",
    "type" : "ENDPOINT"
  }, {
    "key" : "ss2018_t",
    "name" : "SS2018 T",
    "type" : "ENDPOINT"
  } ],
  "rows" : [ [ "000", "Papillary (8130/2, 8131/2, other histologies, see code 050)\n- Non-infiltrating or non-invasive papillary transitional cell carcinoma\n- Non-infiltrating or non-invasive papillary urothelial carcinoma\n- Papillary transitional cell carcinoma, with inferred description of non-invasion\n- Papillary urothelial carcinoma, with inferred description of non-invasion", "VALUE:Ta", "VALUE:IS" ], [ "050", "Nonpapillary\n- Carcinoma in situ, NOS \n- Sessile (flat) (solid) carcinoma in situ   \n- Transitional cell carcinoma in situ\n- Urothelial carcinoma (in situ, non-infiltrating, non-invasive)\n\nMultifocal papillary and nonpapillary non-invasive tumors (see Note)\n\nWITH no stromal invasion and involvement of\n* Periurethral or prostatic ducts\n* Prostatic urethra", "VALUE:Tis", "VALUE:IS" ], [ "100", "Subepithelial connective tissue (lamina propria, submucosa) invaded\n\nLocalized, NOS", "VALUE:T1", "VALUE:L" ], [ "300", "Prostate (prostatic stroma)\nProstatic ducts", "VALUE:T2", "VALUE:RE" ], [ "400", "Bladder neck\nPeriprostatic fat (beyond prostate capsule)", "VALUE:T3", "VALUE:RE" ], [ "700", "Adjacent organ(s), NOS\nBladder wall\nExtraprostatic invasion bladder wall\nRectal wall   \n\nFurther contiguous extension", "VALUE:T4", "VALUE:D" ], [ "800", "No evidence of primary tumor", "VALUE:T0", "VALUE:U" ], [ "999", "Unknown; extension not stated\nPrimary tumor cannot be assessed \nNot documented in medical record\n\nDeath Certificate Only", "VALUE:TX", "VALUE:U" ] ]
}